retatrutide cardiovascular effects and Risk: Evaluating Heart Rate and Outcomes Retatrutide Isn't a Weight Loss

Readout is also expected in Q2-Q3 2026

Evidence-Based Management of MASLD and MASH in Patients with Obesity Date: Friday, April 25, 2025 Time: 1:50 PM 2:35 PM East Coast USA Time Location: Potomac AB Description: Up to 90% of individuals with obesity are affected by Metabolic Associated Steatotic Liver Disease (MASLD), and a significant number are at risk of progressing to Metabolic Associated Steatohepatitis (MASH) and liver fibrosis

Pederson, R

And big questions remain, starting with: Will these meds improve your health in the long run, and if so, how

Retatrutide (LY3437943) is a synthetic triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly, enabling simultaneous modulation of appetite, glycemic control, energy expenditure, and lipid metabolism

Standard-dose protocols may produce stronger appetite suppression, but they can also create a higher likelihood of noticeable side effects during escalation